

EPIDERMAL GROWTH FACTOR RECEPTORS IN OVARIAN NEOPLASMS

*Thesis Submitted for the Partial Fulfillment
of M.D. Degree in Obstetrics & Gynecology*


By

Yasser Galal Moustafa

M.B., B.Ch., M.Sc

Assistant Lecturer of Obstetrics & Gynecology

Ain Shams University



Supervised by

Prof. Dr. Ahmed Galal El-Laithy

Professor of Obstetrics & Gynecology

Ain Shams University

Prof. Dr. Ibrahim Yassien Abou-Senna

Professor of Obstetrics & Gynecology

Ain Shams University

Dr. Essam Mohamad Khater

Assistant Professor of Obstetrics & Gynecology

Ain Shams University

Dr. Magda Hassan Abdel-hamid

Assistant Professor of Pathology

Ain Shams University

Faculty of Medicine

Ain Shams University

1995



بسم الله الرحمن الرحيم

قالوا سبحانهم لا علم لنا إلا ما علمتنا
إنهم أنت العليم الخبير

بسم الله العظيم

سورة البقرة (٢٢)



ACKNOWLEDGEMENT

I wish to express my gratitude and respectful thanks to Prof. Dr. Ahmed Galal El-Laithy, Professor of Obstetrics and Gynaecology, Faculty of Medicine, Ain Shams University, for his help, valuable remarks, constructive criticism and meticulous review of this work. His precious guidance, which was given, is beyond acknowledgement.

I am deeply grateful to Prof. Dr. Ibrahim Yassien Abou-Senna, Professor of Obstetrics and Gynaecology, Faculty of Medicine, Ain Shams University, for his support, unforgettable assistance, encouragement and help.

Appreciation is due to Prof. Dr. Essam Mohamed Khater, Assistant Professor of Obstetrics and Gynaecology, Ain Shams University, for his cardinal support and kind help during this study and his true assistance in fulfilling this work.

I wish to express my deepest gratitude to Dr. Magda Hassan Abdel Al-Hamid, Assistant Professor of Pathology, Ain Shams University who offered much of her time and experience for providing me with a helpful advise, and suggestions throughout the practical part of this work.

Many heart felt thanks to professor Khalil El-Lamie, Head of Obst. and Gyn. Department, Ain-Shams University, for his sincere guidance and help, as most of my specimens were brought from the operations for ovarian cancer, he has performed himself. Actually, what he has taught me has greatly inspired my future.

To my father, my mother, my brother, my wife and my son, I wish to express my thanks for their tolerant support throughout this work and always.

"TO ALL PATIENTS IN AIN SHAMS MATERNITY HOSPITAL"

With the help of these kind patients

We will be surgeons,

Teachers,

Researchers

LIST OF ABBREVIATIONS

Abbreviation	Meaning
A	Adenine
ABC	Avidin-biotin complex (immunoperoxidase) technique
AF	Amniotic fluid
ATP	Adenosine triphosphate
C	Cytosine
CIN	Cervical intraepithelial neoplasia
COOH	Carboxyl terminus of EGF
CSF	Colony stimulating factors
DAG	Diacylglycerol
DNA	Dioxyribonucleic acid
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptor
ER	Estrogen receptors
Er	Endoplasmic reticulum
FGR	Fibroblast growth factor
G0	Resting gap of cell cycle
G1	Gap phase (1) of cell cycle
G2	Gap phase (2) of cell cycle
G	Guanine
G-CSF	Granulocyte colony stimulating factor
GM-CSF	Granulocyte-macrophage colony stimulating factor
GTP	Guanithedin triphosphate
HCG	Human chorionic gonadotrophins hormone
HPL	Human placental lactogen hormone
HPV	Human papilloma virus
HRP	Horseradish plant
IGF-I	Insulin like growth factor one
IGF-II	Insulin like growth factor two
IH	Immunohistochemistry method
IL-3	Interlukin 3
IP	Inositol phosphate lipid cycle
IP3	Inositol triphosphate
LBA	Ligand binding assay
M	Mitotic phase of cell cycle
Mab	Monoclonal antibodies
M-CSF	Macrophages colony stimulating factor
m-RNA	messenger ribonucleic acid
Multi-CSF	Multiple colony stimulating factor
NH3+	Amino acid terminus of EGF
Os	Overall survival
P	Phosphoric acid
P53	Tumour suppressor gene
PDGF	Platelet derived growth factor
PFS	Progression free survival

Abbreviation	Meaning
PG	Prostaglandin
PgR	Progesterone receptors
PIP2	Phosphatidyl inositol 4, 5 biphosphate
PK1-3	Protein kinase 1, 2 and 3
PKC	Protein kinase C
RFS	Relapse free survival
RNA	Ribonucleic acid
rRNA	ribonucleic acid
S	DNA synthesis phase of cell cycle
s	Deoxy ribose sugar of DNA
T	Thymine
TGF-alpha	Transforming growth factor alpha
TGF-beta	Transforming growth factor beta
t-RNA	Transfer RNA

List of Tables

Table No.	Page
(1) Growth factors.....	47
(2) The incidence of EGFR positivity in ovarian cancer among different investigators.....	106
(3) The International Federation of Gynaecology and Obstetrics (FIGO) staging for ovarian malignancy.....	126
(4) Shows the pathology of benign ovarian neoplasms.....	165
(5) Shows the pathology of malignant ovarian neoplasms.....	166
(6) Shows the distribution of histopathological type grade among malignant ovarian tumours.....	168
(7) Shows range, median and mean of age among the benign and malignant ovarian neoplasm patients.....	169
(8) Shows the reproductive state among both benign and malignant ovarian neoplasm patients.....	170
(9) Shows the tumour stages among patients with malignant ovarian neoplasms at staging laparotomy.....	171
(10) Shows the state of lymph nodes during laparotomy operations among patients with malignant ovarian neoplasms.....	171
(11) Shows the results of the cytoreduction operations among patients with malignant ovarian neoplasms.....	172
(12) Shows the results of the cytoreduction operations according to the tumour stages.....	172
(13) Shows the results of the cytoreduction operations and tumour pathology.....	173
(14) Shows the ranges and means of preoperative CA125 among benign and malignant ovarian neoplasms.....	174
(15) Shows the sensitivity and specificity of pre-operative CA125 among patients of ovarian neoplasms.....	175

(16) Shows the incidence of EGFR in normal postmenopausal ovaries.....	176
(17) Shows the distribution of EGFR in premenopausal normal ovaries during the follicular phase of ovarian cycles.....	177
(18) Shows the distribution of EGFR in premenopausal normal ovaries during the luteal phase of ovarian cycle.....	178
(19) Shows the incidence and number of EGFR positivity among benign and malignant ovarian neoplasms.....	179
(20) Shows the intensity of staining for EGFR (EGFR score) among the different ovarian neoplasms.....	180
(21) The distribution of EGFR according to the histopathological subtypes among patients with malignant ovarian neoplasms.....	182
(22) Shows the results of chi-square test for testing the relationship between histopathological subtypes and distribution of EGFR among patients with malignant ovarian neoplasms.....	183
(23) Shows the distribution of EGFR according to the tumour grade among patients with malignant ovarian neoplasms.....	184
(24) Shows the results of chi-square test in investigating the correlation between the EGFR expression and tumour grades.....	185
(25) Shows the relation between EGFR state to age and parity of patients with malignant ovarian neoplasms.....	186
(26) Shows the results of chi-square test in investigating the relation between reproductive state and the distribution of EGFR among different malignant ovarian neoplasms.....	187
(27) Shows the mean, SD and range of EGFR status among patients with malignant ovarian neoplasms.....	188
(28) Shows the relation between the local lymph node metastases and EGFR status among patients with malignant ovarian neoplasms.....	189

Table No.	Page
(29) Shows the EGFR status in relation to the results of cytoreduction operations (optimal versus suboptimal).....	190
(30) Shows the distribution of EGFR in relation to tumour stage among the patients with malignant ovarian neoplasms.....	191
(31) Shows the clinical features and EGF receptor status among patients with poor prognostic outcome.....	193
(32) Shows the pathological features and EGF receptors status among patients with poor prognostic outcome.....	194
(33) Shows the survival state, duration of overall survival, time of relapse (progression free survival) and EGFR status among patients with malignant ovarian neoplasms and had poor prognostic outcome.....	195
(34) Shows the relation between relapse and patients' survival.....	196
(35) Shows the mean and SD of the duration of progression free survival in relation to EGFR status among patients who died of their disease during the course of followup.....	1
(36) Shows the mean and SD of the duration of progression free survival in relation to EGFR status among all patients with poor prognostic outcome.....	1
(37) Shows the mean and SD of the duration of overall survival in relation to EGFR status among patients who died of their disease.....	200
(38) Shows the EGFR status in relation to the different prognostic outcome among all evaluable patients with malignant ovarian neoplasms.....	201
(39) Shows the EGFR status among patients with malignant ovarian neoplasms, comparing between patients with favorable prognosis and patients who died of their disease.....	202
(40) Shows the EGFR status among patients with malignant ovarian neoplasms, comparing between patients with favorable prognosis to patients who had their tumours progressed but still alive.....	203

(41) Shows the EGFR status in relation to the prognosis of patients with malignant epithelial ovarianeoplasms.....	205
(42) Shows the EGFR status in relation to the prognosis among patients with epithelial ovarian malignant neoplasms (favorable versus died).....	205
(43) Shows the EGFR status in relation to prognosis among patients with epithelial ovarian neoplasms (favorable versus progressive tumours but alive).....	206
(44) Shows the prognostic significance of patients'age.....	207
(45) Shows the prognostic significance of reproductive state.....	208
(46) Shows the prognostic significance of tumours' histopathologicalsubtypes.....	209
(47) Shows the prognostic significance of tumours' histopathologicalgrading.....	210
(48) Shows the prognostic significance of preoperative CA125 in predicting tumour relapse.....	211
(49) Shows the prognostic significance of preoperative CA125 in predicting survival of patients.....	212
(50) Shows the prognostic significance of tumour stage in predicting tumour relapse.....	213
(51) Shows the prognostic significance of tumour stage in predicting patient's survival.....	214
(52) Shows the prognostic significance of lymph node metastasis in predicting tumour relapse.....	215
(53) Shows the prognostic significance of tumour residuals in predicting tumour relapse after primarycytoreductionoperation.....	215
(54) Shows the prognostic significance of tumour residuals in predicting survival of patients.....	215

(55) Shows the relation between EGFR status and prognosis (relapse versus no relapse) among patients with advanced stages (III and IV) malignant ovarian neoplasms.....	217
(56) Shows the relation between EGFR status and survival (alive versus died) among patients with advanced stages (III and IV) malignant ovarian neoplasms.....	218
(57) Shows the relation between EGFR status and relapse of tumours (relapse versus no relapse) among patients with optimal cytoreduced tumours.....	220
(58) Shows the relation between EGFR status and survival (alive versus died) among patients with optimal cytoreduced tumours.....	220
(59) Shows the relation between EGFR status and preoperative CA125 in predicting survival (alive versus died) among patients with malignant ovarian neoplasms.....	221

List of Pictures

Picture No.	Page
(1) : EGF-receptor immunohistochemistry system (oncogene science).....	158
(2) : Positive control slide x 100.....	222
(3) : Negative control slide x 100.....	222
(4) : Negative immunostaining for EGFR in primordial and preantral follicles x 250.....	223
(5) : Positive (+) immunostaining of EGFR in antral follicle x 400.....	223
(6) : Negative immunostaining of EGFR in corpus albican x 400.....	224
(7) : Negative immunostaining of EGFR in postmenopausal ovary x 250.....	224
(8) : Negative immunostaining of EGFR in simple serous cyst of the ovary x 100.....	225
(9) : Positive (+) immunostaining of EGFR in simple mucinous cyst of the ovary x 400.....	225
(10): Negative immunostaining of EGFR in papillary serous cystadenoma of the ovary x 250.....	226
(11): Positive (+++) immunostaining of EGFR in (G1) papillary serous carcinoma of the ovary x 250.....	226
(12): Positive (++) immunostaining of EGFR in (G2) serous cystadenocarcinoma of the ovary x 250.....	227
(13): Positive (++) immunostaining of EGFR in endometroid carcinoma of the ovary x 250.....	227
(14): Positive (+) immunostaining of EGFR in metastatic serous cystadenocarcinoma in the omentum x 100.....	228

**Picture
No.**

Page

- (15): Positive (+) immunostaining of EGFR in clear cell carcinoma of the ovary x 250.....228
- (16): Negative immunostaining of EGFR in metastatic endometroid adenocarcinoma into the colon x 100.....229
- (17): Positive (+++) immunostaining of EGFR in malignant mixed mullerian tumour of the ovary x 250.....229
- (18): Positive immunostaining (+++) for epidermal growth factor receptors in pemmomatous serous carcinoma of the ovary 230
- (19): Positive immunostaining for epidermal growth factor receptors (+) in embryonal carcinoma of the ovary x 250..... 230

List of Figures

Figure No.	Page
(1) : Structure of the cell.....	1
(2) : Structure of the cell membrane.....	1
(3) : The double-strand structure of DNA.....	1
(4) : Steps of protein synthesis in the cell.....	1
(5) : Steps of cell division.....	2
(6) : Modes of delivery of growth factors.....	2
(7) : Schematic outlines of signal transduction.....	2
(8) : The cell cycle.....	3
(9) : Diagram shows the use of X-linked isoenzyme cell markers as evidence of monoclonality of neoplasms.....	3
(10): a- Mechanism of action of oncogenes & suppressor genes in normal cells.....	38
b- Mechanism of action of oncogenes & suppressor genes in cancer cells.....	38
(11): Cellular genes in which mutations produce transformation.....	4
(12): Mechanisms by which an oncogene may produce cell growth.....	4
(13): Incorporation of a viral oncogene into eukaryotic DNA.....	4
(14): Flow chart depicts a simplified scheme of cancer pathogenesis.....	4
(15): Synergistic action of certain growth factors in the cell cycle.....	5
(16): Signal transduction and growth regulation by growth factor and receptors.....	5